Investors & Media

Transformative science, targeted medicines

Blueprint Medicines, a Sanofi company, is a fully integrated global biopharmaceutical company that invents life-changing medicines across two strategic focus areas of allergy/inflammation and oncology/hematology. Our approach combines deep scientific expertise, modality-agnostic drug discovery capabilities, and a proven track record of R&D success. Currently, we are commercializing our approved medicine AYVAKIT/AYVAKYT® (avapritinib) in the U.S. and Europe, as well as in other regions of the world through partnerships.

Biography

<< Back

Sherwin Sattarzadeh

Chief Business Officer

Sherwin is a seasoned business leader with over 20 years of experience in the biopharmaceutical industry. He has served as Chief Business Officer since February 2025, previously serving in leadership roles including Senior Vice President of Strategic Operations, Chief of Staff to the CEO and COO, and Head of Regulatory Affairs since joining the company in 2015. A member of the Executive Team, he has led and contributed to portfolio strategy, business development and alliance management priorities, including the integration of Lengo Therapeutics, collaborations with F. Hoffman-La Roche, CStone Pharmaceuticals, Zai Lab and Ipsen, and the sale of GAVRETO® (pralsetinib) to Rigel Pharmaceuticals. During his tenure, Sherwin has helped grow and scale the company from a preclinical organization to a global fully integrated commercial stage biopharmaceutical company. Prior to joining Blueprint Medicines, Sherwin held various leadership positions in the oncology and rare disease business units at Genzyme, a Sanofi Company. During his regulatory career, he led registration programs resulting in U.S. and global approvals of AYVAKIT® (avapritinib) and GAVRETO, as well as CERDELGA® (eliglustat) and MOZOBIL® (plerixafor). Sherwin received a BSc in Organic Chemistry from the University of British Columbia and an MBA from Boston University.